OncoDxRx’s OncoMRD (Monitoring Residual Disease) technology is one of the most advanced MRD assay in service today, designed to revolutionize tumor tracking by offering unmatched detection capabilities against residual tumor activity at extreme sensitivity.

At the heart of OncoMRD’s advantage is its patient-unique gene expression signature, which allows it to capture signals from both tumor and non-tumor microenvironment. Unlike traditional MRD testing, which only detects tumor DNA mutations by whole genome/exome sequencing, the OncoMRD can measure “tumor activity” dynamically. This results in a significantly extended functional genomics spectrum, enabling it to detect, identify and track overactive genes at scopes well beyond those of conventional DNA-based MRD assays.

OncoMRD employs a cancer type-specific panel, designed to engage key biomarkers in tumor and it’s surrounding microenvironment. This high-end profiling technology, combined with the patient-derived gene signature, ensures that the assay can adjust to target maneuvers, interactions, and environmental changes in real time. The measurement of OncoMRD is highly specific, providing an overwhelming advantage in contested clinical settings.

The combination of its gene panel design and personalized gene patterning makes OncoMRD one of the most sensitive and specific MRD assay for solid tumor in existence.
Integration of OncoMRD has been a key focus for molecular diagnostic labs, with platforms such as qPCR and dPCR all could incorporate it into their capabilities.

OncoMRD’s ability to sustain quick turnaround, high throughput, low cost, adapt to dynamic testing workflows, and easy implementation makes it a defining technology in the modern precision oncology landscape. As cancer threats evolve and tumor clonal evolution advances, the OncoMRD ensures that the labs carrying it remain at the forefront of counter-cancer superiority.

OncoMRD represents a generational shift in residual disease monitoring technology, providing OncoDxRx with a crucial edge in assessing therapeutic efficacy, relapse risk and disease prognosis.